Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01627041 · ClinicalTrials.gov registry record · Phase 2
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
A Phase 2 study of Acute Myeloid Leukemia and Secondary Acute Myeloid Leukemia, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
- 9
- Study locations
NCT01627041 is a Phase 2 study of Acute Myeloid Leukemia and Secondary Acute Myeloid Leukemia that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 178 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (55% higher). The trial reports 9 study locations across 3 states.
The verdict
NCT01627041, a Phase 2 study of Acute Myeloid Leukemia and Secondary Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
- 9
- Study locations
Study Summary
This randomized phase II trial studies how well decitabine works when given together with daunorubicin hydrochloride and cytarabine in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, daunorubicin hydrochloride, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Decitabine may help daunorubicin hydrochloride and cytarabine kill more cancer cells by making them more sensitive to the drugs. It is not yet known whether low-dose decitabine is more effective than high-dose decitabine when giving together with daunorubicin hydrochloride and cytarabine in treating acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG Decitabine
- OTHER Laboratory Biomarker Analysis
- DRUG Cytarabine
- DRUG Daunorubicin Hydrochloride
- OTHER Pharmacological Study
Study Locations (9)
New York
- Roswell Park Cancer Institute - Buffalo
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- NYP/Weill Cornell Medical Center - New York
- Montefiore Medical Center-Weiler Hospital - The Bronx
- Montefiore Medical Center - Moses Campus - The Bronx
Ohio
- Case Western Reserve University - Cleveland
- Ohio State University Comprehensive Cancer Center - Columbus
Maine
- Lafayette Family Cancer Center-EMMC - Brewer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2011-09-16 |
| Est. Completion | 2027-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01627041
The ClinicalTrials.gov registry entry for NCT01627041 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (55% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Decitabine is the first listed.
NCT01627041 reports 9 study locations spanning 3 distinct geographic areas - top geographies include New York, Ohio, Maine.
Frequently Asked Questions
What is clinical trial NCT01627041 about?
NCT01627041 is a clinical study titled "Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia". This randomized phase II trial studies how well decitabine works when given together with daunorubicin hydrochloride and cytarabine in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, daunorubicin hydrochloride, and cytarabine, work in different ways to ...
What is the current status of trial NCT01627041?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2011-09-16. Estimated completion is 2027-02-01.
What conditions does trial NCT01627041 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia.
What interventions are being tested in trial NCT01627041?
The interventions under investigation include: Decitabine (DRUG), Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Daunorubicin Hydrochloride (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01627041?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01627041 being conducted?
This trial has 9 study locations across Maine, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.